Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, With Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase

NCT02991469 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02991469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02991469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, With Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Recruiting
Start date
August 9, 2018
Completion date
January 17, 2031
Enrollment
51 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis